The Market Herald - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Genetic Signatures has undertaken an institutional placement that will raise $35 million
  • A total of 35.7 million shares were issued at a price of $0.98 per share
  • In conjunction, a share purchase plan will be made with permitted shareholders able to apply for up to $30,000 worth of shares
  • Genetic Signatures is currently down 4.63 per cent with shares trading for $1.03 apiece

Genetic Signatures has successfully undertaken an institutional placement that will raise $35 million.

A total of 35.7 million new ordinary shares were issued at a price of $0.98 per share, this represents a 9.3 per cent discount to the closing price of $1.08 on Wednesday, October 23.

This placement will be issued in two phases with phase one consisting of 15.6 million shares to raise $15.3 million and phase two will issue the remaining 20.1 million shares to raise $19.7 million.

However, this is subject to obtaining shareholder approval.

The money raised will be used for the commercial expansion in the European Union and the USA, obtaining further regulatory approvals for its products, additional product development, and working capital purposes.

The placement received overwhelming support from offshore investors and domestic institutional investors.

Large global fund manager, Perennial Value Management and Regal Funds Management played a large role in the placement.

“We are delighted with the significant broadening of our institutional register and the strong continued support from our existing shareholders, with demand for the placement exceeding the funds raised,” Chief Executive John Melki said.

“Genetic Signatures is well funded to execute its commercial expansion strategy in Europe and the United States,” he added.

In conjunction with the placement, a share purchase plan (SPP) will also be made to eligible shareholders.

Under the SPP those who are permitted shareholders in Australia or New Zealand will be invited to apply for up to $30,000 of new fully paid shares.

The aim of the SPP is to raise $2 million. Genetic Signatures has ended the day down 4.63 per cent with shares trading for $1.03 apiece in a $107.1 million market cap.

GSS by the numbers
More From The Market Herald

Cynata Therapeutics receives approval to launch phase two trial of CYP-001 in Turkey

Cell therapy company, Cynata Therapeutics (ASX:CYP) has received regulatory and ethics approval to commence a phase…

Little Green Pharma positions itself for growth in France’s emerging medicinal cannabis market

Little Green Pharma (ASX:LGP) is primed for substantial growth after a major amendment to the French…

PolyNovo posts $8m sales month and $9m revenue month for November

Disruptive medical device company PolyNovo (ASX:PNV) has announced record monthly sales of $8.8 million for November…
Imugene (ASX:IMU) - Managing Director & CEO, Leslie Chong

Imugene set to secure European patent for cancer vaccine; announces new phase II CRC cancer trial in 2024

Imugene (ASX:IMU) is on the verge of securing approval from the European Patent Office (EPO) for…